This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA's Oncologic Drugs Advisory Committee is scheduled to review the injectable cisplatin/epinephrine gel Sept. 10 for treatment of recurrent or refractory head and neck cancer. Matrix plans a conference call after the meeting to discuss results of the review. The company hopes to launch IntraDose by January 2002. An NDA for the agent was submitted Jan. 4
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.